Logo image of CORT

CORCEPT THERAPEUTICS INC (CORT) Stock Fundamental Analysis

NASDAQ:CORT - Nasdaq - US2183521028 - Common Stock - Currency: USD

70.86  -2.24 (-3.06%)

After market: 70.86 0 (0%)

Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to CORT. CORT was compared to 194 industry peers in the Pharmaceuticals industry. CORT scores excellent points on both the profitability and health parts. This is a solid base for a good stock. CORT is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings would make CORT suitable for growth and quality investing!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

In the past year CORT was profitable.
CORT had a positive operating cash flow in the past year.
In the past 5 years CORT has always been profitable.
CORT had a positive operating cash flow in each of the past 5 years.
CORT Yearly Net Income VS EBIT VS OCF VS FCFCORT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

1.2 Ratios

With an excellent Return On Assets value of 15.83%, CORT belongs to the best of the industry, outperforming 97.42% of the companies in the same industry.
CORT has a Return On Equity of 19.61%. This is amongst the best in the industry. CORT outperforms 92.78% of its industry peers.
The Return On Invested Capital of CORT (13.61%) is better than 90.72% of its industry peers.
CORT had an Average Return On Invested Capital over the past 3 years of 17.94%. This is above the industry average of 14.87%.
The 3 year average ROIC (17.94%) for CORT is well above the current ROIC(13.61%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 15.83%
ROE 19.61%
ROIC 13.61%
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
CORT Yearly ROA, ROE, ROICCORT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

1.3 Margins

CORT has a better Profit Margin (19.55%) than 93.30% of its industry peers.
In the last couple of years the Profit Margin of CORT has declined.
The Operating Margin of CORT (16.17%) is better than 85.05% of its industry peers.
CORT's Operating Margin has declined in the last couple of years.
CORT's Gross Margin of 98.43% is amongst the best of the industry. CORT outperforms 98.45% of its industry peers.
CORT's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 16.17%
PM (TTM) 19.55%
GM 98.43%
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
CORT Yearly Profit, Operating, Gross MarginsCORT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), CORT is creating some value.
The number of shares outstanding for CORT has been increased compared to 1 year ago.
CORT has less shares outstanding than it did 5 years ago.
There is no outstanding debt for CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CORT Yearly Shares OutstandingCORT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CORT Yearly Total Debt VS Total AssetsCORT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

CORT has an Altman-Z score of 30.22. This indicates that CORT is financially healthy and has little risk of bankruptcy at the moment.
CORT has a Altman-Z score of 30.22. This is amongst the best in the industry. CORT outperforms 94.33% of its industry peers.
CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 30.22
ROIC/WACC1.34
WACC10.12%
CORT Yearly LT Debt VS Equity VS FCFCORT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.3 Liquidity

A Current Ratio of 3.07 indicates that CORT has no problem at all paying its short term obligations.
CORT has a Current ratio (3.07) which is in line with its industry peers.
A Quick Ratio of 2.96 indicates that CORT has no problem at all paying its short term obligations.
CORT has a Quick ratio (2.96) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.07
Quick Ratio 2.96
CORT Yearly Current Assets VS Current LiabilitesCORT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

9

3. Growth

3.1 Past

CORT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.43%, which is quite good.
The Earnings Per Share has been growing by 9.71% on average over the past years. This is quite good.
CORT shows a strong growth in Revenue. In the last year, the Revenue has grown by 30.93%.
The Revenue has been growing by 17.11% on average over the past years. This is quite good.
EPS 1Y (TTM)9.43%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-32%
Revenue 1Y (TTM)30.93%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%7.09%

3.2 Future

CORT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 56.00% yearly.
The Revenue is expected to grow by 30.41% on average over the next years. This is a very strong growth
EPS Next Y13.31%
EPS Next 2Y47.92%
EPS Next 3Y70.13%
EPS Next 5Y56%
Revenue Next Year29.79%
Revenue Next 2Y32.48%
Revenue Next 3Y32.46%
Revenue Next 5Y30.41%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CORT Yearly Revenue VS EstimatesCORT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
CORT Yearly EPS VS EstimatesCORT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 10 15

5

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 61.09, the valuation of CORT can be described as expensive.
CORT's Price/Earnings ratio is a bit cheaper when compared to the industry. CORT is cheaper than 79.38% of the companies in the same industry.
CORT is valuated expensively when we compare the Price/Earnings ratio to 27.54, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 26.12, CORT can be considered very expensive at the moment.
70.10% of the companies in the same industry are more expensive than CORT, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.44, CORT is valued a bit cheaper.
Industry RankSector Rank
PE 61.09
Fwd PE 26.12
CORT Price Earnings VS Forward Price EarningsCORT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

76.80% of the companies in the same industry are more expensive than CORT, based on the Enterprise Value to EBITDA ratio.
CORT's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. CORT is cheaper than 79.38% of the companies in the same industry.
Industry RankSector Rank
P/FCF 42.41
EV/EBITDA 61.79
CORT Per share dataCORT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
CORT has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as CORT's earnings are expected to grow with 70.13% in the coming years.
PEG (NY)4.59
PEG (5Y)6.29
EPS Next 2Y47.92%
EPS Next 3Y70.13%

0

5. Dividend

5.1 Amount

CORT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CORCEPT THERAPEUTICS INC

NASDAQ:CORT (7/18/2025, 5:56:02 PM)

After market: 70.86 0 (0%)

70.86

-2.24 (-3.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-05 2025-05-05/amc
Earnings (Next)07-30 2025-07-30/amc
Inst Owners79.51%
Inst Owner Change-0.55%
Ins Owners6.55%
Ins Owner Change0.39%
Market Cap7.51B
Analysts82
Price Target141.01 (99%)
Short Float %12.2%
Short Ratio7.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.62%
Min EPS beat(2)-40.2%
Max EPS beat(2)16.96%
EPS beat(4)3
Avg EPS beat(4)13.93%
Min EPS beat(4)-40.2%
Max EPS beat(4)42.54%
EPS beat(8)7
Avg EPS beat(8)20.33%
EPS beat(12)9
Avg EPS beat(12)10.46%
EPS beat(16)12
Avg EPS beat(16)11.02%
Revenue beat(2)0
Avg Revenue beat(2)-11.81%
Min Revenue beat(2)-13.38%
Max Revenue beat(2)-10.25%
Revenue beat(4)2
Avg Revenue beat(4)-4.03%
Min Revenue beat(4)-13.38%
Max Revenue beat(4)4.07%
Revenue beat(8)6
Avg Revenue beat(8)-0.63%
Revenue beat(12)7
Avg Revenue beat(12)-1.42%
Revenue beat(16)8
Avg Revenue beat(16)-1.72%
PT rev (1m)0%
PT rev (3m)-2.98%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-50.33%
EPS NY rev (1m)0%
EPS NY rev (3m)-18.73%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.98%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)-0.7%
Valuation
Industry RankSector Rank
PE 61.09
Fwd PE 26.12
P/S 10.96
P/FCF 42.41
P/OCF 41.87
P/B 11
P/tB 11
EV/EBITDA 61.79
EPS(TTM)1.16
EY1.64%
EPS(NY)2.71
Fwd EY3.83%
FCF(TTM)1.67
FCFY2.36%
OCF(TTM)1.69
OCFY2.39%
SpS6.46
BVpS6.44
TBVpS6.44
PEG (NY)4.59
PEG (5Y)6.29
Profitability
Industry RankSector Rank
ROA 15.83%
ROE 19.61%
ROCE 15.76%
ROIC 13.61%
ROICexc 25.27%
ROICexgc 25.27%
OM 16.17%
PM (TTM) 19.55%
GM 98.43%
FCFM 25.85%
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
ROICexc(3y)74.13%
ROICexc(5y)85.06%
ROICexgc(3y)74.13%
ROICexgc(5y)85.06%
ROCE(3y)20.79%
ROCE(5y)23.98%
ROICexcg growth 3Y-18.86%
ROICexcg growth 5Y-17.58%
ROICexc growth 3Y-18.86%
ROICexc growth 5Y-17.58%
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
F-Score6
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion 159.44%
Profit Quality 132.22%
Current Ratio 3.07
Quick Ratio 2.96
Altman-Z 30.22
F-Score6
WACC10.12%
ROIC/WACC1.34
Cap/Depr(3y)72.82%
Cap/Depr(5y)100.78%
Cap/Sales(3y)0.15%
Cap/Sales(5y)0.19%
Profit Quality(3y)125.51%
Profit Quality(5y)133.52%
High Growth Momentum
Growth
EPS 1Y (TTM)9.43%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-32%
EPS Next Y13.31%
EPS Next 2Y47.92%
EPS Next 3Y70.13%
EPS Next 5Y56%
Revenue 1Y (TTM)30.93%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%7.09%
Revenue Next Year29.79%
Revenue Next 2Y32.48%
Revenue Next 3Y32.46%
Revenue Next 5Y30.41%
EBIT growth 1Y-9.1%
EBIT growth 3Y3.23%
EBIT growth 5Y4.18%
EBIT Next Year20.41%
EBIT Next 3Y47.8%
EBIT Next 5Y19.15%
FCF growth 1Y60.04%
FCF growth 3Y5.38%
FCF growth 5Y7.73%
OCF growth 1Y61.51%
OCF growth 3Y5.66%
OCF growth 5Y7.79%